Lilly’s Investigational Triple Agonist Retatrutide Reduces OSA Severity in Phase 3 Trial
2 Articles
2 Articles
The results recently reported by pharmacist Eli Lilly on retatrutide, an experimental medication for the treatment of obesity, have attracted the attention of the international medical community. The data from the phase 3 study TRIUMPH-1 indicate an average weight loss of up to 28.3% after 80 weeks of treatment, performance that approximates the results traditionally observed in patients undergoing bariatric surgery. The research evaluated 2,339…
Lilly’s Investigational Triple Agonist Retatrutide Reduces OSA Severity in Phase 3 Trial
Phase 3 TRIUMPH-1 trial data show retatrutide reduced the AHI by up to 36.1 events per hour alongside substantial weight loss. Key takeaways: Retatrutide reduced moderate-to-severe OSA severity by up to 36.1 events per hour (60.6%) from a baseline of 58.6 events per hour. In the TRIUMPH-1 trial, participants on the highest dose (12 mg) lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30. The findings were pres…
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
